What are the side effects of Semax?
Semax exhibits a relatively mild side effect profile based on available research. Most reported issues are mild and transient. However, the evidence base primarily comes from animal studies and a limited number of human clinical trials conducted in Russia. No large, long-term safety studies have been published in Western peer-reviewed literature to date, meaning the full picture of Semax's long-term effects in the human body remains incomplete.
What we know comes from decades of Russian clinical use, a handful of published human studies, and extensive animal research. Collectively, this evidence base does not indicate significant safety signals—but it does not provide the level of assurance that comes with fully approved drugs. This is an important distinction.
The most commonly reported side effects in clinical human use concern mild irritation at the application site. When using a standard nasal spray where the solution is administered directly into the nasal cavity, some users experience mild discomfort, temporary burning, or general nasal irritation. Beyond these local effects, some patients in clinical stroke trials reported minor reactions; however, overall tolerability was described as good across different patient groups, including the elderly [1].
In one of the early clinical trials, the first injection of Semax caused brief episodes of atypical brain electrical activity, detected by EEG, in some patients with post-hypoxic traumatic brain injury. This led the authors to recommend monitoring brain electrical activity during the first administration of Semax in this specific group of patients [2]. This finding is of clinical significance, however, it applies exclusively to patients with pre-existing brain damage and should not be directly extrapolated to healthy users.
Does Semax cause headaches?
Headache is not a clearly reported side effect in the published clinical literature for Semax. However, a lack of reporting does not definitively rule it out—available human studies were not designed to systematically track all adverse events according to modern drug safety trial standards.
The nasal route of administration—administering a liquid solution into the nasal cavity—can occasionally cause mild discomfort or a feeling of pressure in the head due to the mechanical delivery process. Some users may describe this as a headache. No published studies have shown headache as a frequent or clinically significant adverse event following Semax use.
In online nootropic communities, anecdotal reports of headaches among some users have emerged, but these cannot be systematically evaluated—they may reflect individual variability, differences in product quality, or interactions with other substances being taken concurrently.
Does Semax cause nausea?
Nausea is not a documented side effect in the published research literature concerning Semax. Animal studies on the effects of Semax on the gastrointestinal tract have actually suggested the opposite effect—Semax protected the gastric mucosa from damage caused by alcohol, immobilization stress, and non-steroidal anti-inflammatory drugs, and also accelerated the healing of existing stomach ulcers [3], [4]. In clinical trials of patients with gastric ulcer disease receiving Semax as an adjunct to standard therapy, the peptide was well-tolerated with no reported gastrointestinal problems [5].
The absence of nausea in published reports is consistent with Semax's lack of hormonal activity and its non-stimulatory pharmacological profile. However, it is worth noting that systematic monitoring of nausea was not the primary focus in most studies, so mild nausea in some individuals cannot be entirely ruled out.
Does Semax affect blood pressure?
The effect of Semax on blood pressure is not a serious safety concern based on available evidence, although the picture is complex. In a rat myocardial infarction model, Semax did not directly affect overall cardiac function or mean arterial pressure at the tested doses. However, it partially prevented the increase in left ventricular end-diastolic pressure—a pressure that abnormally rises when the heart is under stress—and improved structural cardiac regeneration after infarction [6].
In a separate cardiological study, Semax reduced the density of sympathetic nerve endings—nerve fibers that carry stress signals—in the arteries of rats following myocardial infarction, and decreased arterial sensitivity to nerve stimulation and norepinephrine [7]. These effects theoretically would lean towards a moderate decrease in blood pressure rather than an increase.
The anti-stress and antithrombotic properties of Semax—including the prevention of stress-induced blood clotting—suggest an overall cardiovascular protective, rather than destabilizing, profile [8]. However, no dedicated human study has directly measured the effect of Semax on blood pressure as a primary endpoint. Individuals with cardiovascular diseases should exercise caution and consult with their physician.
Does Semax affect blood sugar levels?
There is limited but significant evidence that Semax may affect blood sugar levels and fat metabolism. In a study on rats with experimentally induced diabetes, Semax at a dose of 200 micrograms per kilogram corrected impaired lipid metabolism—it lowered total cholesterol, triglycerides, and LDL, while increasing HDL—although the effect was less pronounced than with the comparator drug [9].
In patients with psoriasis who also had metabolic syndrome—including elevated blood sugar, abnormal lipid profile, and excess abdominal fat—adding Semax to standard treatment resulted in a significant reduction in cholesterol, triglycerides, and LDL compared to standard therapy alone [10].
These results suggest metabolic effects worth monitoring, especially in individuals with diabetes or metabolic disorders. However, no dangerous fluctuations in glucose levels were observed in healthy individuals. Individuals with diabetes or metabolic disorders should be aware of these potential effects and consult with a doctor before considering the use of Semax.
What are the psychological side effects of Semax?
The psychological side effects of Semax documented in the research literature are generally mild. In many cases, they are desirable rather than undesirable effects—such as reduced anxiety, improved mood, and increased alertness. The only psychological effects that might be considered truly undesirable in healthy individuals are potential overstimulation or increased vigilance in some users, though this has not been systematically documented in clinical trials.
In an EEG study of healthy volunteers, Semax induced changes in brain electrical activity patterns [11], which were not associated with any reported symptoms or discomfort. The antidepressant and anxiolytic effects documented in animal studies are generally considered beneficial [12]. However, in susceptible individuals, any factor modulating serotonin and dopamine activity could theoretically affect mood in unpredictable ways.
No published studies have reported serious psychiatric adverse events—such as psychosis, mania, or severe anxiety—following administration of Semax in either animals or humans.
Is Semax safe?
Based on available research, Semax appears to be well-tolerated in the short term. No serious adverse events have been reported in human clinical trials published to date. However, it cannot be described as definitively safe; long-term human safety data simply does not exist in sufficient quantity or quality to warrant such a determination.
This is an important distinction. A lack of reported serious harm in limited studies is not the same as proven safety. Semax has been used clinically in Russia since the 1990s for the treatment of stroke and cerebrovascular diseases – and during this time, no serious safety signals have emerged in the Russian medical literature. A review of the 15-year development period of Semax published in 1997 explicitly stated that in all clinical cases studied, the peptide showed positive effects and in no case did it cause negative side effects or complications associated with its administration [1]. This is an encouraging historical safety record, but it comes from an era and regulatory environment with different standards for tracking and reporting adverse events than those required today.
Is Semax well tolerated?
Clinical evidence consistently describes Semax as well-tolerated across various patient populations, including elderly patients post-stroke. In a clinical study of cerebrovascular insufficiency involving 187 patients, Semax was also particularly well-tolerated by the elderly, with only a small percentage of adverse effects reported [13].
In a study of acute ischemic stroke, 30 patients received Semax as part of intensive combination therapy without reporting.
These observations are consistent across multiple clinical contexts. However, all studies were relatively small, and none were specifically designed or statistically powered to detect rare adverse events that may only emerge in larger populations.
In preclinical safety studies, Semax and related peptides did not elicit toxic effects on mouse embryonic stem cells across a broad range of concentrations from 0.1 to 10 micromolar [16], suggesting a lack of embryotoxic effects in cellular models. However, these results cannot be directly extrapolated to the safety of use during pregnancy in humans.
What are the risks of using Semax?
Identifiable risks of Semax based on current evidence include: local nasal irritation with intranasal administration, potential interactions with cardiovascular medications or conditions due to effects on vascular tone and blood clotting, the possibility of unpredictable reactions in individuals with specific neurological or psychiatric conditions, and the general risks associated with the use of any compound whose long-term effects in humans have not been fully characterized.
The discovery that Semax occasionally caused short EEG changes in patients after cerebral hypoxia [2] suggests that individuals with existing seizure disorders or significantly impaired brain function should approach it with particular caution and only under direct medical supervision.
Semax also exhibits copper-chelating properties, meaning it can bind copper ions and remove them from copper-protein complexes in the body [17]. While this might be beneficial in the context of Alzheimer's pathology, it could theoretically affect copper-dependent biochemical processes with long-term use, as copper is an essential mineral involved in many normal biological functions. However, no studies have reported copper deficiency or related adverse effects after Semax administration.
Is Semax safe for long-term use?
No published studies have directly assessed the long-term safety of using Semax for months or years in humans. This is one of the most significant gaps in the entire body of research literature on Semax.
Studies of chronic administration in animals—typically lasting days to weeks, rather than months—have not revealed progressive toxicity, organ damage, or worsening outcomes with continued use [12], [18]. Rats receiving multiple doses of Semax exhibited lasting behavioral benefits without signs of tolerance or harm. The rapid enzymatic breakdown of Semax—into biologically active but non-accumulating fragments—makes tissue accumulation over time pharmacokinetically unlikely.
However, the lack of data on toxicity in short courses in animals does not replace proper long-term safety studies in humans. Such studies have not been conducted. Anyone considering long-term use of Semax is acting far beyond the scope of what published scientific evidence can confirm in terms of safety.
Who should not use Semax?
Based on available evidence and sound medical caution, certain groups should avoid Semax or use it only under direct medical supervision.
Pregnant and breastfeeding women should avoid it as there are no human reproductive and developmental safety data, and peptides that cross the blood-brain barrier could theoretically affect fetal or infant brain development. Children and adolescents should also avoid it, as the developing brain may respond differently to compounds affecting neurotrophic factors and neurotransmitter systems, and no pediatric safety data exist.
Individuals with seizure disorders or epilepsy should exercise particular caution due to EEG changes observed in certain patient groups [2]. Individuals taking anticoagulant medications should be aware of the documented effects of Semax on blood coagulation and fibrinolysis [8], as there is a theoretical risk of interaction. Individuals with hypersensitivity to any component of Semax should avoid it.
Because Semax is not an approved drug in most countries, there are no official contraindication guidelines from regulatory agencies. The above precautions are based on pharmacological reasoning from published research rather than official prescribing recommendations.
What do studies say about Semax's safety in specific organ systems?
Studies on the effects of Semax on individual organ systems do not reveal clear signs of toxicity in any specific system.
In the liver, Semax exerted a protective effect on liver cells in both acute and chronic stress conditions—normalizing liver enzyme levels and restoring proper protein synthesis [19, 20]. These results are consistent with organ protection, not toxic damage.
In a study on rats, Semax at appropriate doses prevented stress-induced deterioration of the intestinal membrane and maintained healthy gut bacterial populations [21], which again suggests a protective rather than harmful effect on gastrointestinal tissue.
In the heart, Semax demonstrated cardioprotective effects in myocardial infarction models – it protected cardiac muscle cells and limited the harmful overactivation of the sympathetic nervous system [6], [7].
Overall, organ-level evidence does not indicate toxicity in any specific system at the doses used in the studies. However, formal dose-escalation toxicology studies and dedicated organ safety studies in humans remain unpublished.
Does Semax cause addiction?
Semax does not appear to be addictive based on its known pharmacological properties and the absence of addictive behaviors in published research literature. Addiction typically involves direct and potent stimulation of the brain's reward system through large dopamine release—particularly in an area called the nucleus accumbens—which creates reinforcing, compulsive drug-seeking behaviors.
Semax does not directly trigger dopamine release under normal conditions. It only enhances existing dopaminergic responses to other stimuli [22]. No studies have reported reward-related behaviors, self-administration, or conditioned place preference—a standard animal addiction test—after administration of Semax.
Semax's mechanism of action—through increased neurotrophic factors, modulation of gene expression, and fine-tuning of neurotransmitter systems—is fundamentally different from the mechanisms driving addiction to substances like opioids, stimulants, or benzodiazepines.
One discovery is worth noting: Semax inhibits enzymes that break down enkephalins—the brain's own natural painkillers—in human blood [23]. Modulation of the enkephalin system may contribute to potentiating effects for certain compounds. However, the indirect and limited nature of this effect, coupled with a lack of any signals of addiction over decades of clinical and research use, does not warrant classifying Semax as a substance with significant addictive potential.
The recent identification of the μ-opioid receptor as a molecular target of Semax in studies of spinal cord injury [24] adds theoretical considerations. However, the context is mechanistically distinct from opioid addiction: Semax interacts with this receptor to regulate cellular waste processing and neuroprotection, rather than to induce analgesia or the euphoria associated with addictive opioids.
Does Semax cause tolerance?
No published studies have reported the development of tolerance with Semax use. Tolerance means the need for increasingly higher doses over time to achieve the same effect—a characteristic feature of many addictive substances.
In studies of chronic administration for 10–14 days in rats, persistent and progressive behavioral improvements were observed without any signs of waning response. The anxiolytic and antidepressant effects actually appeared to intensify rather than diminish with continued dosing [12].
Semax's neurotrophic mechanism of action—which involves altering gene expression and stimulating the brain's own growth factor production, rather than directly and repeatedly activating a single receptor—is not associated with the receptor downregulation typically driving tolerance. Receptor downregulation is a process in which cells decrease the number of available receptors for a substance when it is continuously present, making the substance gradually less effective.
However, it should be noted that no systematic tolerance studies investigating the requirements for dose escalation over a longer period have been published in humans. The absence of evidence is not the evidence of absence, and this remains a recognized gap in the literature.
Does stopping Semax cause withdrawal symptoms?
No withdrawal symptoms have been noted after discontinuation of Semax in either clinical or preclinical literature. Withdrawal syndromes occur when the brain has physically adapted to the continuous presence of a substance and has difficulty functioning normally after its sudden removal—which is well-documented for alcohol, benzodiazepines, opioids, and some stimulants.
Semax's pharmacological profile — with a relatively short duration of direct receptor activity, a lack of direct dopaminergic stimulation, and the absence of physical dependence mechanisms — does not suggest the occurrence of withdrawal syndrome. Clinical trials using Semax in specific treatment courses — typically 10-day courses, sometimes repeated — have not described any negative rebound effects after the course ended [13], [14]. Animal studies concerning chronic administration and subsequent withdrawal behavioral tests also did not record any deterioration below pretreatment levels.
What happens after stopping Semax?
Based on available evidence, discontinuation of Semax does not cause withdrawal symptoms or a decline below baseline. The most likely outcome of stopping use is a gradual return to baseline cognitive and neurological functions as the neurotrophic and neuromodulatory effects wear off—however, without the negative rebound effect characteristic of true substance withdrawal.
In the context of post-stroke rehabilitation, the beneficial effects on BDNF levels and functional recovery observed during Semax treatment persisted throughout the observation period [25], suggesting that at least some of the benefits—particularly those mediated by structural neuroplastic changes induced by sustained BDNF increase—may outlast the direct pharmacological activity of the peptide.
The durability of cognitive improvements observed in the spatial memory study—where the memory-restoring effect persisted long after the 6-day treatment course concluded [26]—further supports the idea that some of Semax's benefits may be self-sustaining through its induced neuroplastic changes, even after the peptide itself is no longer present.
Is Semax detected in doping tests?
No published research has analyzed the detectability of Semax in standard drug tests in urine or blood. Standard screening panels detect specific classes of substances—opioids, stimulants, cannabinoids, benzodiazepines, and cocaine—none of which are structurally related to Semax. A routine workplace drug test would not detect Semax, as it is not included in any standard testing panel.
Specialized analytical methods using liquid chromatography coupled with mass spectrometry—an advanced laboratory technique capable of identifying specific molecules at very low concentrations—can detect Semax and Selank in seized pharmaceutical preparations [27]. This indicates that targeted forensic analysis can identify these peptides when specifically looking for them. Whether any sports, military, or security organization currently tests for Semax is not documented in peer-reviewed literature. Semax is not on the World Anti-Doping Agency's (WADA) prohibited substances list based on available evidence, and no published cases of positive anti-doping tests related to Semax have been reported.
Can Semax cause cancer or tumor growth?
No published studies have reported tumor growth or cancer promotion with Semax. A study specifically analyzing the effect of Semax on spontaneous cancer development in mice found no evidence that the peptide promotes tumor growth [28].
The BDNF increase induced by Semax deserves theoretical attention. BDNF signaling through the TrkB receptor has been studied in the context of some types of cancer, as BDNF can promote cell survival and growth—properties beneficial in healthy brain tissue, but potentially relevant in cancer biology. However, no direct evidence linking Semax administration to cancer development or progression has been published in any study.
Embryonic stem cell safety studies confirmed that Semax did not induce toxic effects and did not dramatically alter stem cell differentiation patterns [16]. This is an important context for understanding its effects on rapidly dividing cells.
The decades of Russian clinical use without tumor signals are reassuring. However, formal carcinogenicity studies—specifically designed to test whether a substance can cause cancer with prolonged exposure—have not been published for Semax, and this remains an acknowledged gap in long-term safety data.
Disclaimer
This article is for educational and informational-scientific purposes only and should not be interpreted as medical advice, diagnosis, therapeutic recommendation, or a claim regarding the safety or efficacy of Semax for the treatment of any medical condition. Semax remains an investigational compound in most countries, including the United States and most European countries, and is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition. It is approved and used clinically in Russia and some Eastern European countries. Most of the evidence presented in this article is derived from preclinical animal studies and a limited number of human clinical trials. Additional, well-designed clinical trials are needed to more definitively establish the safety, efficacy, mechanisms of action, and long-term effects of Semax in humans.
References
[1] Ashmarin, I. P., Nezavibat’ko, V. N., Miasoedov, N. F., Kamenskiĭ, A. A., Grivennikov, I. A., Ponomareva-Stepnaia, M. A., Andreeva, L. A., Kaplan, A. Ia., Koshelev, V. B., & Riasina, T. V. (1997). A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study). Journal of Higher Nervous Activity named after I. P. Pavlov, 47(2), 420–430. PMID: 9173745
[2] Alekseeva, G. V., Bottaev, N. A., & Goroshkova, V. V. (1999). Use of Semax in the follow-up of patients with posthypoxic encephalopathy. Anesthesiology and Resuscitation, (1), 40–43. PMID: 10199046
[3] Zhuikova, S. E., Smirnova, E. A., Bakaeva, Z. V., Samonina, G. E., & Ashmarin, I. P. (2000). Effect of Semax on homeostasis of gastric mucosa in albino rats. Bulletin of Experimental Biology and Medicine, 130(9), 871–873. PMID: 11177268
[4] Zhuĭkova, S. E., Badmaeva, K. E., Samonina, G. E., & Plesskaia, L. G. (2003). Semax and some glyproline peptides accelerate the healing of acetic ulcers in rats. Experimental and Clinical Gastroenterology, (4), 88–92. PMID: 14653248
[5] Ivanikov, I. O., Brekhova, M. E., Samonina, G. E., Myasoedov, N. F., & Ashmarin, I. P. (2002). Therapy of peptic ulcer with semax peptide. Bulletin of Experimental Biology and Medicine, 134(1), 73–74. https://doi.org/10.1023/a:1020621124776
[6] Gavrilova, S. A., Golubeva, A. V., Lipina, T. V., Fominykh, E. S., Shornikova, M. V., Postnikov, A. B., Andrejeva, L. A., Chentsov, Yu. S., & Koshelev, V. B. (2006). Protective effect of peptide semax on the rat heart after myocardial infarction. I.M. Sechenov Physiological Journal of Russia, 92(11), 1305–1321. PMID: 17385423
[7] Gorbacheva, A. M., Berdalin, A. B., Stulova, A. N., Nikogosova, A. D., Lin, M. D., Buravkov, S. V., Gavrilova, S. A., & Koshelev, V. B. (2016). Changes in sympathetic innervation of rat caudal artery in experimental myocardial infarction: Effect of Semax peptide. Bulletin of Experimental Biology and Medicine, 161(4), 476–480. https://doi.org/10.1007/s10517-016-3442-y
[8] Grigorjeva, M. E., & Lyapina, L. A. (2010). Anticoagulation and antiplatelet effects of semax under conditions of acute and chronic immobilization stress. Bulletin of Experimental Biology and Medicine, 149(1), 44–46. https://doi.org/10.1007/s10517-010-0871-x
[9] Elagina, A. A., Lyashev, Yu. D., Lyashev, A. Yu., Pronyaeva, T. V., & Chahine, A. R. (2020). Correction of lipid metabolism disorders in diabetes mellitus with peptide drugs. Bulletin of Experimental Biology and Medicine, 168(5), 618–620. https://doi.org/10.1007/s10517-020-04764-2
Dontsova, E. V. (2015). Possible drug correction of lipid metabolism disturbances associated with metabolic syndrome in patients with psoriasis. Experimental and Clinical Pharmacology, 78(12), 30–33. PMID: 27051926
[11] Koroleva, M. V., Meizerov, E. E., Nezavibat'ko, V. N., Kamenskii, A. A., & Dubynin, V. A. (1996). Effect of the heptapeptide Semax on the human electroencephalogram. Bulletin of Experimental Biology and Medicine, 121(1), 116–117. PMID: 8679991
[12] Inozemtseva, L. S., Yatsenko, K. A., Glazova, N. Yu., Kamensky, A. A., Myasoedov, N. F., Levitskaya, N. G., Grivennikov, I. A., & Dolotov, O. V. (2024). Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. European Journal of Pharmacology, 984, 177068. https://doi.org/10.1016/j.ejphar.2024.177068
Gusev, E. I., Skvortsova, V. I., & Chukanova, E. I. (2005). Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Journal of Neurology and Psychiatry named after S.S. Korsakov, 105(2), 35–40. PMID: 15792140
[14] Gusev, E. I., Skvortsova, V. I., Miasoedov, N. F., Nezavibat'ko, V. N., Zhuravleva, E. Yu., & Vanichkin, A. V. (1997). Effectiveness of Semax in the acute period of hemispheric ischemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 97(6), 26–34. PMID: 11517472 https://pubmed.ncbi.nlm.nih.gov/11517472/
Serdiuk, A. V., Levitskiĭ, G. N., Miasoedov, N. F., & Skvortsova, V. I. (2007). The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax. Journal of Neurology and Psychiatry named after S.S. Korsakov, 107(4), 29–39. PMID: 18379501 https://pubmed.ncbi.nlm.nih.gov/18379501/
Kobylyanskii, A. G., Zolotarev, Yu. A., Andreeva, L. A., Grivennikov, I. A., & Myasoedov, N. F. (2017). Studying the toxic effects of some biologically active peptides on the model of mouse embryonic stem cells. Bulletin of Experimental Biology and Medicine, 163(6), 731–736. https://doi.org/10.1007/s10517-017-3891-y
[17] Tomasello, M. F., Di Rosa, M. C., Naletova, I., Sciacca, M. F. M., Giuffrida, A., Maccarrone, G., & Attanasio, F. (2025). Semax, a copper chelator peptide, decreases the Cu(II)-catalyzed ROS production and cytotoxicity of Aβ by metal ion stripping and redox silencing. Bioinorganic Chemistry and Applications, 2025, 4226220. https://doi.org/10.1155/bca/4226220
[18] Vilensky, D. A., Levitskaya, N. G., Andreeva, L. A., Alfeeva, L. Yu., Kamensky, A. A., & Myasoedov, N. F. (2007). Effects of chronic Semax administration on exploratory activity and emotional reaction in white rats. Sechenov Physiological Journal of Russia, 93(6), 661–669. PMID: 17850024
Ivanov, A. V., Bobyntsev, I. I., Shepeleva, O. M., Kryukov, A. A., Andreeva, L. A., & Myasoedov, N. F. (2017). Influence of ACTG4-7-PGP (Semax) on morphofunctional state of hepatocytes in chronic emotional and painful stress. Bulletin of Experimental Biology and Medicine, 163(1), 105–108. https://doi.org/10.1007/s10517-017-3748-4
[20] Bobyntsev, I. I., Shepeleva, O. M., Kryukov, A. A., Ivanov, A. V., & Belykh, A. E. (2015). The effect of peptide ACTH4-7-PGP on functional hepatocyte state in rats in acute and chronic foot-shock stress. Sechenov Physiological Journal of Russia(2), 171–179. PMID: 26012109
Morphofunctional state of the large intestine in rats under conditions of restraint stress and administration of peptide ACTH(4-7)-PGP (Semax). Bulletin of Experimental Biology and Medicine, 170(3), 384–388. https://doi.org/10.1007/s10517-021-05072-z
[22] Eremin, K. O., Kudrin, V. S., Saransaari, P., Oja, S. S., Grivennikov, I. A., Myasoedov, N. F., & Rayevsky, K. S. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493–1500. https://doi.org/10.1007/s11064-005-8826-8
[23] Kost, N. V., Sokolov, O. Yu., Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. A., Miasoedov, N. F., & Zozulia, A. A. (2001). Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorganic Chemistry, 27(3), 180–183. https://doi.org/10.1023/a:1011373002885
[24] Liu, R., Chen, Y., Huang, H., Li, X., Lv, J., Jiang, L., Jiang, H., Wu, C., Chen, W., Xu, H., Zhu, Z., Cai, H., Xiao, J., Yin, L., & Ni, W. (2025). Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. British Journal of Pharmacology, 182(22), 5489–5516. https://doi.org/10.1111/bph.70122
Gusev, E. I., Martynov, M. Yu., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 118(3), 61–68. https://doi.org/10.17116/jnevro20181183261-68
[26] Silachev, D. N., Shram, S. I., Shakova, F. M., Romanova, G. A., & Myasoedov, N. F. (2009). Formation of spatial memory in rats with ischemic lesions to the prefrontal cortex. Neuroscience & Biobehavioral Reviews(8), 749–756. https://doi.org/10.1007/s11055-009-9197-4
[27] Vanhee, C., Francotte, A., Janvier, S., & Deconinck, E. (2020). The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations. Drug Testing and Analysis, 12(3), 371–381. https://doi.org/10.1002/dta.2717
[28] Meshavkin, V. K., Kost, N. V., Sokolov, O. Yu., Andreeva, L. A., & Myasoedov, N. F. (2013). The influence of oligopeptides on spontaneous carcinogenesis in mice. Doklady Biological Sciences, 449, 79-81. https://doi.org/10.1134/S0012496613020087